LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

Jan 13, 2025 · Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune ® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.

Mar 29, 2023 · Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune ® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.

LIBTAYO is a prescription medicine used to treat people with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI.

What is LIBTAYO? LIBTAYO is a prescription medicine used to treat: people with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC). LIBTAYO may be used to treat CSCC that has spread or cannot be cured by surgery or radiation. people with a type of skin cancer called basal cell carcinoma (BCC).

Feb 22, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50% ...

Jun 2, 2022 · Regeneron, which has money to spend after its COVID-19 antibody treatment generated $6.2 billion in 2021, sees the full rights to Libtayo as a chance to start to become a major player in...

Nov 9, 2022 · After weeks of an inspection-related delay, Regeneron has finally won a much-anticipated FDA approval for Libtayo in newly diagnosed non-small cell lung cancer (NSCLC), opening another front to...

Jan 14, 2025 · Regeneron Pharmaceuticals on Monday presented positive Phase III data for its PD-1 inhibitor Libtayo, which yielded significant survival benefits when used as an adjuvant treatment for patients with high-risk cutaneous squamous cell carcinoma.

Oct 10, 2024 · The biggest turning point for Regeneron is still on the horizon, but not far off, Lowy said. The company’s lead oncology candidate is a combination of Libtayo and a LAG-3 inhibitor called fianlimab, which could together rival BMS’ already …